Work Strand 3 focuses on stratification through assessment of the host genome
Identifying the genetic variants that influence clinically relevant treatment phenotypes may give insight into disease biology, which can inform on potential biomarkers or therapeutic targets. Genetic variants may also be used to stratify individuals on the basis of their predisposition to disease progression (e.g. liver cancer in patients with cirrhosis), treatment response or drug-associated side effects.
The objective of this Work Strand is to use a combination of genome-wide SNP arrays, DNA and RNA sequencing and direct genotyping to investigate the potential for patient stratification based on host genetics.This Work Strand is led by Dr Chris Spencer (University of Oxford).